期刊文献+

HIV-1 Gag蛋白酵母表达产物的纯化及免疫原性检测

Purification of HIV-1 Gag protein expressed in Pichia pastoris and analysis of its immunogenicity
下载PDF
导出
摘要 目的 纯化HIV 1Gag蛋白 ,并检测其免疫原性。方法 将表达HIV 1Gag蛋白的酵母工程菌GS115 /pPICGAG接种到YPD培养基中多次传代后 ,用PCR检测其目的基因。该酵母工程菌在BMMY培养基中经甲醇诱导表达 ,上清液初步浓缩后上柱进行凝胶过滤层析 ,并将纯化蛋白免疫Balb/c小鼠 ,检测其血清抗体水平。结果 该酵母工程菌经多次传代后外源基因不丢失。Westernblot检测结果表明纯化蛋白具有很好的反应原性 ,其纯度可达 85 %。纯化蛋白免疫小鼠后可诱导特异性抗体产生。结论 表达HIV 1Gag蛋白的酵母工程菌具有很好的遗传稳定性 。 Objective To purify HIV-1 Gag protein and analyze its immunogenicity. Methods The engineering yeast strain GS115/pPICGAG expressing the HIV-1 Gag protein was inoculated into YPD medium and subcultured continuously, and the gene-of-interest was detected by PCR. After the engineering yeast strain expressed in BMMY medium under the induction of methanol, the supernatant of the culture was condensed and loaded into the chromatographic column for gel filtration chromatography. Balb/c mice were immunized with the purified protein and the serum antibody level was measured. Results The engineering yeast strain didn't lose the exogenous gene after the subculture. Western blot analysis showed that the purified protein had good reactogenicity with a purity of 85%. The purified protein could induce the specific antibodies in mice. Conclusion The engineering yeast strain expressing the HIV-1 Gag protein has good genetic stability and its expressed products can elicit the specific humoral immune response in mice.
出处 《免疫学杂志》 CAS CSCD 北大核心 2004年第4期307-309,共3页 Immunological Journal
基金 国家"8 63"基金资助项目 (2 0 0 1AA2 1 50 31 )
关键词 HIV-1 GAG 毕赤酵母 纯化 免疫原性 HIV-1 gag Pichia pastoris Purification Immunogenicity
  • 相关文献

参考文献10

  • 1Wagner R, Fliessbach H, Wanner G, et al. Studies on processing, particle formation and immunogenicity of the HIV-1gag gene product: A possible component of a HIV vaccine[J]. Arch Virol, 1992, 127(1/4): 117-137.
  • 2Faber KN, Harder W, Ab G, et al. Review methylotrophic yeasts as factories for the production of foreign proteins[J].Yeast, 1995, 11(14): 1 331-1 344.
  • 3Cregg JM, Vedvick TS, Raschke WC. Recent advances in the expression of foreign genes in Pichia pastoris [J]. Biotechnology, 1993, 11(8): 905-910.
  • 4Spence RP, Japvill MW, Ferns RB. The cloning and expressing in E. coli of sequences coding for p24, the core protein of hunan immunodeficiency virus, and the use of the recombinant protein in characterizing a panel of monoclonal antibodies against the vir
  • 5Royer M, Cerutti M, Gay B, et al. Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells[J]. Virology, 1991, 184(1): 417-422.
  • 6Haffar O, Garrignes J, Travis B, et al. Hunan immunodeficiency virus-like nonreplicating, gag-env particles assemble in a recombinant vaccina virus expression system[J]. J Virol,1990, 64(6): 2 653-2 659.
  • 7Vernon SK, Murthy S, Wilhelm J, et al. Ultrastructural characterization of human immumodeficiency virus type 1gag-containing particles assembled in a recombinant adenovirus vector system [J]. J Gen Virol, 1991, 72 (Pt6):1 243-1 251.
  • 8张应玖,金宁一,沈家骢.艾滋病疫苗的研究[J].免疫学杂志,2000,16(z1):72-74. 被引量:3
  • 9江文正,金宁一,王宏伟,金洪涛,张应玖,王海燕.应用毕赤酵母表达中国株HIV-1核心蛋白Gag[J].中国生物制品学杂志,2002,15(2):72-74. 被引量:1
  • 10金冬雁 黎孟枫译.分子克隆实验指南[M],2版[M].北京:科学出版社,1992.18-68.

二级参考文献28

  • 1[1]MICHAEL BALTER . Global program struggles to stem the flood of new cases[J]. Science, 1998, 280 (5 371):1 863-1 866.
  • 2[2]DAVID D HO. Toward HIV eradication or remission: the tasks ahead[J]. Science ,1998,280(5 371): 1 866-1 870.
  • 3[3]MONTERFIOR DC,MOORE JP. Magic of the Occult[J]. Science, 1999,283(5 400): 336- 337.
  • 4[4]BALTIMORE D,HEILMAN C. Prospects and challenges[J]. Sci Am, 1998,279(1): 98-103.
  • 5[5]NORMAN L,LETVI N. Progress in the development of an HIV- 1 vaccine [J]. Science, 1998,280 ( 5 371 ): 1875-1 880.
  • 6[6]PEET NM,MCKEATING JA,RAMOS B,et al. Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV-1 gp120[J]. Clin Exp Immunol, 1997,109 (2): 226-232.
  • 7[7]SATTENTAU Q J,MOULARD M,BRIVET B,et al.Antibody neutralization of HIV-1 and the potential for vaccine design[J]. Immunol Lett, 1999,66( 1~3): 143-149.
  • 8[8]COHEN J. At conference,hope for success is further attenuated[J]. Science,1994,266(5 188): 1 154.
  • 9[9]MONTAGNIER L. Nef vaccination against HIV disease[J]. The Lancet ,1995,346(8 983):1 170.
  • 10[10]HAYAMI M,IGARASHI T,KUWATA T. Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use [J]. AIDS Res Hum Retroviruses, 1999,13(Suppl. 1 ) :S42-S47.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部